5
10
3
↑5
↓10
—3
Evidence suggests Semaglutide maydecreaseObesity.
27 studies (18 claims)
Emerging evidence
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| semaglutide 2.4 mg once weekly | Decreases - has been submitted for approval | obesity | Human | patients with obesity (body mass index [BMI] ≥30 kg/m²) | — | Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? |
| semaglutide 2.4 mg | No effect - approved for treatment | obesity | Human | — | Not specified | Weight Loss Pharmacotherapy: Current and Future Therapies.cited 1× |
| GLP-1RA liraglutide and semaglutide | No effect - paved way to | a ground-breaking therapy specific for obesity | Human | — | — | GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? |
| STEP 2.4 mg/week semaglutide program | No effect - shown with | therapy specific for obesity | Human | — | — | GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? |
| Glucagon-like peptide 1 (GLP-1) agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists such as semaglutide and tirzepatide | No effect - are approved | management of obesity | Human | — | — | Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity? |
| GLP-1 agonist semaglutide | Decreases - confirmed safety and efficacy | obesity | Human | patients with HFpEF | Not Assessed | Obesity and Weight Loss Strategies for Patients With Heart Failure.cited 6× |
| semaglutide | Decreases - was associated with lower rates | composite obesity-associated cancers | Human | individuals with overweight/obesity and type 2 diabetes | — | Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study. |
| Semaglutide | Increases - demonstrated benefit with an acceptable side effect profile | MAFLD and obesity | Human | patients with MAFLD and obesity | Not mentioned | Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications.cited 1× |
| semaglutide | No effect - therapy | obesity | Human | — | Liraglutide 3 mg daily, semaglutide 2.4 mg once weekly | GLP-1 physiology informs the pharmacotherapy of obesity.cited 223× |
| semaglutide | Decreases - has revolutionized the treatment | obesity | Human | obese patients | Not specified | Novel neural pathways targeted by GLP-1R agonists and bariatric surgery.cited 1× |
| semaglutide | No effect - discusses the efficacy and safety | obesity | Human | patients with pre-obesity/obesity | — | Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. |
| semaglutide (SEM) | No effect - approved for the treatment of | obesity | Human | patients with or without type 2 diabetes mellitus (T2DM) | — | An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database. |
| semaglutide | Decreases - would avert | obesity cases | Human | 126 million eligible US adults | — | Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. |
| semaglutide | Increases - are effective medication options | obesity management | Human | — | — | Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity. |
| semaglutide | Decreases - long-term results are now approaching the success seen with bariatric surgery | obesity treatment | Human | — | Not specified | Obesity and diabetes: the final frontier. |
| semaglutide | Decreases - long-term results are now approaching the success seen with bariatric surgery | obesity treatment | Human | — | Not specified | Obesity and diabetes: the final frontier. |
| semaglutide | No effect - are effective and well-tolerated treatments | T2DM and obesity | Human | patients with T2DM and obesity | — | Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review. |
| semaglutide | Increases - seems to be an effective treatment option | treatment for obesity | Human | both men and women | Supervised walking (specific duration/frequency not detailed) combined with hydroxycitric acid, 4667 mg 3 times daily, and a 2000-kcal/d diet. | Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.cited 3× |
| Semaglutide | Decreases - constitutes an effective and widely used treatment | type 2 diabetes and obesity | Human | — | Not specified | Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26. |
| new agents such as Semaglutide and Tirzepatide | No effect - offers promising alternatives | obesity treatment | Human | — | Not specified | Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. |
| new agents such as Semaglutide and Tirzepatide | No effect - offers promising alternatives | obesity treatment | Human | — | Not specified | Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. |
| glucagon-like peptide 1 (GLP-1) mimetics semaglutide and liraglutide | No effect - approved for management of | obesity | Human | patients independent of type 2 diabetes | — | NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management? |
| GLP-1 receptor agonists such as liraglutide and semaglutide | No effect - have emerged as promising therapeutic options | obesity management | Human | — | — | GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly. |